Psychological Symptoms of Finasteride

Finasteride, a 5α-reductase inhibitor widely used for male androgenetic alopecia and benign prostatic hyperplasia has gained popularity, especially among patients seeking hair restoration via medical therapy or transplantation. While its efficacy in reducing dihydrotestosterone (DHT) levels and slowing hair follicle miniaturization is well established, growing attention focuses on possible neuropsychiatric side effects associated with its use. Understanding such risks is particularly important for patients considering long-term therapy and for clinicians advising them especially in the setting of hair transplantation, where expectations and psychological vulnerability may be heightened.

Current safety advice

The European Medicines Agency confirmed suicidal thoughts as a side effect of finasteride 1 mg and 5 mg tablets in 2025; the frequency is unknown. If you take 1 mg for hair loss and develop depressed mood, depression or suicidal thoughts, stop taking it and seek medical advice. If you may harm yourself, seek urgent help. Discuss any past depression or suicidal thoughts with your prescriber before treatment.

Epidemiological and Clinical Evidence

Increased depression, anxiety, suicidal ideation in some users

The cited 2025 study by Gupta and colleagues analysed reports in the FDA Adverse Event Reporting System. It found reporting signals for some psychological adverse events in later study periods, while noting that increased awareness may influence reporting. It was not a meta-analysis and cannot measure how often a side effect occurs among all users.

Moreover, a pharmacovigilance study of post-marketing reports (spontaneous adverse event reporting) identified a disproportionality signal for psychological adverse events and suicidality in patients treated with finasteride especially younger men (aged ≤ 44) using it for hair loss.

A large population-based case-control study comparing users treated for benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA) with matched controls found a modest but statistically significant increased risk of depression and anxiety among AGA patients using finasteride at 1 mg daily.

Mechanism: How Might Finasteride Affect the Brain?

One proposed explanation involves neurosteroids, which help regulate mood and stress responses. Finasteride inhibits 5-alpha reductase, an enzyme involved in their production as well as in DHT production. This is a proposed mechanism; it does not establish why an individual develops symptoms.

Challenges and Limitations

• Causality vs association: Many of the data come from observational studies or spontaneous reporting systems; while they show correlation, establishing a definitive causal link remains difficult. Confounding factors for example, the psychological burden associated with hair loss itself may contribute.
• Psychological vulnerability and baseline risk: Many individuals seeking hair loss treatment may already suffer from body-image distress, low self-esteem, or subclinical psychological issues which could predispose them to mood changes regardless of therapy.
• Underreporting and reporting bias: Spontaneous reporting relies on patients and clinicians recognizing and attributing mental health changes to finasteride.

Clinical Implications

Pre-treatment screening: Before prescribing finasteride particularly for hair loss inquire about personal or family history of mood disorders, depression, suicidal ideation, or other psychiatric vulnerability.

Monitoring: Agree a follow-up plan with your prescriber and report changes in mood or sexual function promptly. Do not wait for a routine appointment if you develop concerning symptoms.

Alternative approaches: In patients with preexisting psychological vulnerability or those willing to avoid pharmacological risk consider alternative treatments (e.g., hair transplantation alone, non-pharmacological strategies, topical therapies when appropriate, though these too are not risk-free) and/or involve psychological support or counselling to manage expectations.

Conclusion

Finasteride can help manage male pattern hair loss, but psychological symptoms deserve attention. Research includes observational studies and spontaneous reports, which have important limitations. These limits do not negate the need to recognise symptoms and act on current safety advice; the frequency of suicidal thoughts associated with finasteride tablets is unknown.

For surgeons, and patients recognizing these risks, transparently discussing them, and monitoring psychological health should be integral parts of care. In selected cases, non-pharmacological alternatives or psychological support may be more appropriate than automatic initiation of finasteride. Continued research is needed to clarify risk factors, mechanisms, and long-term outcomes.